Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034

News | 01. 12. 2015

Chimerix

Opportunity to pursue multiple additional indications for brincidofovir

DURHAM, N.C., Jan. 12, 2015 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a method of synthesis and the commercial morphic form of brincidofovir. With the addition of this most recent patent, composition of matter coverage for brincidofovir in the U.S. is expected to extend to October 2034.

M. Michelle Berrey, M.D. M.P.H., President and CEO, said, “This important allowance significantly increases the patent protection of brincidofovir for our lead indications to prevent clinically significant cytomegalovirus infection in hematopoietic cell transplant recipients and for the treatment of adenovirus infection. Importantly, this will provide 20 years of patent coverage for Chimerix to pursue multiple additional indications in broad patient populations.”